EnWave Corporation

EnWave Corporation

May 01, 2008 08:30 ET

EnWave Receives Positive Shelf-Life Results from Vaccine Dehydration Testing

VANCOUVER, BRITISH COLUMBIA--(Marketwire - May 1, 2008) - EnWave Corporation (TSX VENTURE:ENW)(FRANKFURT:E4U) ("EnWave" or the "Company") is pleased to report that it has received positive results from the Company's first room temperature shelf-life study of dehydrated rotavirus vaccine conducted by its collaboration partner Aridis Pharmaceuticals, LLC ("Aridis") of San Jose, California. The Company believes it is now one step closer to developing a new industry standard technology for dehydrating vaccines and antibodies.

Aridis is testing EnWave's bioREV technology under a Collaboration Agreement to determine the feasibility of dehydrating vaccines and antibodies to produce room temperature stable products as a cost-effective alternative to the industry standard of lyophilization (freeze drying). EnWave believes that the production of dried vaccines and antibodies storable at room temperature could lead to an industry breakthrough by allowing these pharmaceuticals to be shipped worldwide, stored without the need for expensive refrigeration, and stockpiled to protect against pandemic diseases and bioterrorism threats.

During the previous testing stage, Aridis was successful in using bioREV to dry its proprietary rotavirus vaccine with promising bioactivity retention, but discovered a modestly higher residual moisture content than what is typically found in freeze-dried pharmaceutical products and vaccines. To gain a better understanding of the impact of higher moisture on shelf-life, Aridis conducted a 12-week accelerated shelf-life study on the bioREV-dried rotavirus sample to determine how long the vaccine would remain shelf-stable under various temperature conditions. The results of this study indicate that the vaccine samples with 6.5 per cent moisture remained stable throughout the 12-week period both at room temperature (25 degrees C) and at 37 degrees C. This early stage data is positive for EnWave's technology because the stability results are comparable to that of freeze dried vaccines with moisture contents of one to two per cent which require three days to dehydrate, compared to bioREV's 10-minute processing time.

"The results from this preliminary stability study are better than we expected, given that vaccines such as rotavirus are not generally room temperature stable at such high moisture content," said Dr. Vu Truong, Aridis' Vice President of R&D. "Developing a stable vaccine for this childhood disease is particularly important for developing countries where constant product refrigeration is a major challenge."

"This promising post-dehydration shelf-life data brings EnWave one major step forward in providing the vaccine manufacturing industry with the technology to reduce processing time, along with the elimination of the need for constant refrigeration during shipment and storage," said Dr. Tim Durance, Chairman and Co-CEO of EnWave Corporation.

The goals of the Aridis testing program are to establish bioREV processing parameters for optimizing vaccine bioactivity and stability in a dehydrated state. Bioactivity refers to the amount of vaccine survival retained after drying, while stability refers to the ability of the dehydrated vaccine to retain an acceptable level of survival during an extended storage period. Accomplishing both of these goals after bioREV processing is important for establishing a feasible method of dehydration.

EnWave and Aridis will now work together to optimize a modified form of the bioREV technology with new rotavirus vaccine formulations to allow for further reductions in vaccine moisture content. The project team will also undertake a longer term shelf-life study. EnWave expects to receive results from this testing in September 2008. In addition, the two companies are collaborating on the development of a dried salmonella typhoid vaccine ("Ty21a") as well as a vaccine for shigellosis.

About Aridis

Aridis is a privately held biopharmaceutical company formed in 2003, which uses pioneering formulation, processing, and delivery technologies to produce differentiated, high value products. Aridis' goal is to develop therapeutics and vaccines that are more convenient and cost effective for both the recipient and the health professional by simplifying their storage and administration. Their initial products target infectious diseases that have a significant impact on life expectancy, such as infectious diseases in children and cystic fibrosis (CF) in adults and children. Aridis has four licensed products: three with preclinical data, and one with phase II clinical efficacy data. More information about Aridis is available at www.aridispharma.com.

About EnWave

Using proprietary technologies developed in conjunction with the University of British Columbia, EnWave is focused on the development of new methods of dehydrating biological and food materials using Radiant Energy Vacuum technology under its bioREV and nutraREV brands. REV technology combines microwave energy transfer with pressure control to dehydrate and alter structures and drive chemical reactions, thereby creating unique product characteristics for both food products and medical applications that include dry vaccines and antibodies. More information about EnWave is available at www.enwave.net.

EnWave Corporation

Dr. Tim Durance, Chairman & CO-CEO

Safe Harbour for Forward-Looking Information Statements: This release may contain forward-looking information based on management's expectations, estimates and projections. All statements that address expectations or projections about the future, including statements about the Company's strategy for growth, product development, market position, expected expenditures and financial results are forward-looking statements. Forward looking statements in this press release include: "expects to receive". These statements are not guarantees of future performance and involve a number of risks, uncertainties and assumptions: there is no guarantee that the Company's bioREV technology will be developed as a commercial-scale method for dehydrating vaccines and antibodies; even if the Company's bioREV technology can be used as described in this news release, there is no guarantee that such use will result in orders for the Company's bioREV technology. There is no guarantee that the patent subject of this press release will be granted.

The TSX Venture Exchange has neither approved nor disapproved the information contained herein.

Contact Information

  • EnWave Corporation
    Dr. Tim Durance
    Chairman and Co-CEO
    (604) 601-8524
    EnWave Corporation
    Mr. John McNicol
    President and Co-CEO
    (604) 601-8524
    (604) 806-6112 (FAX)
    EnWave Corporation
    Martin Livingston
    Investor Relations
    (604) 657-8234
    Website: www.enwave.net